|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
C4 Therapeutics, Inc. (CCCC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile C4 Therapeutics is a biopharmaceutical company engaged in the development of novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Co.'s primary product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,667 |
| Total Buy Value |
$0 |
$0 |
$0 |
$31,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grogan Donna Roy |
Director |
– • – |
2024-04-01 |
4 |
A |
$8.10 |
$13,746 |
D/D |
1,697 |
23,632 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2024-04-01 |
4 |
A |
$8.10 |
$11,251 |
D/D |
1,389 |
112,351 |
|
- |
|
| Dubin Glenn |
Director |
– • – |
2024-04-01 |
4 |
A |
$8.10 |
$11,000 |
D/D |
1,358 |
22,075 |
|
- |
|
| Hirsch Andrew |
President & CEO |
• • – |
2024-02-15 |
4 |
D |
$7.90 |
$51,824 |
D/D |
(6,560) |
210,741 |
|
- |
|
| Mossler Mark |
Chief Accounting Officer |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,290 |
19,790 |
|
- |
|
| Fisher Stewart |
Chief Scientific Officer |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
27,300 |
129,121 |
|
- |
|
| Schick Kelly |
Chief People Officer |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
27,300 |
52,251 |
|
- |
|
| Hirsch Andrew |
President & CEO |
• • – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
103,400 |
217,301 |
|
- |
|
| Reyno Leonard |
Chief Medical Officer |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
36,700 |
98,000 |
|
- |
|
| Boyle Scott N |
Chief Business Officer |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
27,300 |
52,330 |
|
- |
|
| Adams Kendra |
Chief Financial Officer |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
36,700 |
82,039 |
|
- |
|
| Siegel Jolie |
Chief Legal Officer |
• – – |
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
27,300 |
52,251 |
|
- |
|
| Fisher Stewart |
Chief Scientific Officer |
• – – |
2024-02-13 |
4 |
D |
$6.53 |
$14,725 |
D/D |
(2,255) |
101,821 |
|
- |
|
| Schick Kelly |
Chief People Officer |
• – – |
2024-02-13 |
4 |
D |
$6.53 |
$11,330 |
D/D |
(1,735) |
24,951 |
|
- |
|
| Boyle Scott N |
Chief Business Officer |
• – – |
2024-02-13 |
4 |
D |
$6.53 |
$11,330 |
D/D |
(1,735) |
25,030 |
|
- |
|
| Adams Kendra |
Chief Financial Officer |
• – – |
2024-02-13 |
4 |
D |
$6.53 |
$8,496 |
D/D |
(1,301) |
45,339 |
|
- |
|
| Siegel Jolie |
Chief Legal Officer |
• – – |
2024-02-13 |
4 |
D |
$6.53 |
$11,330 |
D/D |
(1,735) |
24,951 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2024-01-02 |
4 |
A |
$6.52 |
$11,247 |
D/D |
1,725 |
110,962 |
|
- |
|
| Dubin Glenn |
Director |
– • – |
2024-01-02 |
4 |
A |
$6.52 |
$10,999 |
D/D |
1,687 |
20,717 |
|
- |
|
| Grogan Donna Roy |
Director |
– • – |
2024-01-02 |
4 |
A |
$6.52 |
$13,744 |
D/D |
2,108 |
21,935 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2023-10-02 |
4 |
A |
$1.70 |
$11,249 |
D/D |
6,617 |
109,237 |
|
- |
|
| Dubin Glenn |
Director |
– • – |
2023-10-02 |
4 |
A |
$1.70 |
$10,999 |
D/D |
6,470 |
19,030 |
|
- |
|
| Grogan Donna Roy |
Director |
– • – |
2023-10-02 |
4 |
A |
$1.70 |
$13,751 |
D/D |
8,089 |
19,827 |
|
- |
|
| Adams Kendra |
Chief Financial OfficerOfficer |
• – – |
2023-09-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,640 |
|
- |
|
| Adams Kendra |
Chief Financial Officer |
• – – |
2023-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
46,640 |
|
- |
|
166 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
